Ascend Advanced Therapies

It's getting closer now! Our team is excited to kick off the week of August 19th in #Boston at the #CHIBioprocessingSummit. We will start with a presentation on Potency Assays from the brilliant, Huda Naas, and have a full team of #genetherapy advocates in booth TT5 and on the floor. Find us in the show app or reach out at [email protected] to set time.

Developing #quality from the start is critical to #genetherapy success, but it takes commitment. We are thrilled to have employees like Ahmed Youssef and partners like Sartorius Stedim Biotech helping to ensure that we are developing truly scalable processes that can be commercialized. Learn more in this short video:

As July comes to a close, we are three weeks out from the Cambridge Healthtech Institute Bioprocessing Summit. Our team will be onsite in booth TT5 to chat #genetherapy. Will we see you there?

Last month, we had the pleasure of hosting a small group of #genetherapy experts to discuss #industry trends and challenges. Markus Hörer and Sonya Schermann presented how our modular AAV platform and unmatched analytical portfolio are curated to overcome these challenges by balancing high quality, yield and potency from gene to GMP. Thank you to the attendees for making time to provide input on the evolution of our platform here at Ascend. 

Demand for high quality AAV vectors continues to grow, as the number of #genetherapy trials and approvals increases. Let's do a #TBT to the American Society of Gene & Cell Therapy, where our team presented 11 posters at the event! Poster 561 showed how our EpyQ system combines with our suspension HEK293 cell line to create a robust and scalable platform for high quality AAV vector manufacturing. 

The ESACT - European Society for Animal Cell Technology Congress 2024 in Edinburgh did not disappoint! Here's a few photos from our time onsite, which was filled with posters, presentations, intriguing discussions and laughs. It's such a pivotal time in #cellandgenetherapy, and we feel honored to play a part in keeping #genetherapy progress moving ahead.

In a recent chat with our CSO, Markus Hörer, we outlined the importance of AAV process comparability throughout #genetherapy #development. Building processes that are comparable across all scales from R&D through commercial manufacturing from the start simplifies #commercialization. Read the full blog here: https://lnkd.in/eA4KCE9e

What a week with our team in Edinburgh at the ESACT - European Society for Animal Cell Technology Congress digging in to the latest progress in #genetherapy. Stay tuned because we'll take a look back on our adventures there next week. But just in case you missed us onsite or did not make the event at all, we thought we'd share a little about who we are! https://lnkd.in/gWE6ebFe Reach out to chat #innovation any time here or via [email protected].

Have you been wondering how to optimize your rAAV production? And you're at ESACT - European Society for Animal Cell Technology? Check out poster 291 from Johanna Wagner, PhD to learn more. You may even meet the hype team (and our Sunday presenters, Ahmed Youssef and Markus Hörer), too!

Did you start your week in #Edinburgh at the ESACT - European Society for Animal Cell Technology Congress? A handful of our team started with #genetherapy presentations yesterday. And for the duration of the event, check out Johanna Wagner, PhD presenting poster 291 on the impact of the N-1 seed train on rAAV production #efficiency. Missed a presentation or poster, or maybe the whole event? That's okay! We are available at [email protected] any time.